Darmani N A, Zhao W, Ahmad B
Department of Pharmacology, Kirksville College of Osteopathic Medicine, MO 63501, USA.
J Neural Transm (Vienna). 1999;106(11-12):1045-61. doi: 10.1007/s007020050222.
This study introduces Cryptotis parva (the least shrew) as a new dopaminergic animal model of emesis. The potential emetogenic effects of a nonselective dopamine agonist [apomorphine], two D1 agonists [SKF-38393 and SKF-82958], a D2 preferring agonist [quinpirole], and two D3-preferring agonists [7-(OH) DPAT and PD 128, 907] were investigated. Intraperitoneal administration of D1 agonists failed to induce emesis. However, other agonists caused a dose-dependent increase in the percentage of animals vomiting as well as potentiating the mean frequency of emesis with the following ED50, potency order: 7-(OH) DPAT < apomorphine < quinpirole < PD 128, 907. For antagonist studies a 2 mg/kg dose of these agonists were used to induce emesis. Thus, the inhibitory dose-response effects of a D2-preferring [sulpride], a D3-preferring [U 99194A] and combination of varying doses of these antagonists [sulpride + U 99194A] were evaluated on the ability of the cited agonists to produce vomiting. Sulpride decreased the number of shrews vomiting and the mean vomiting frequency produced by the cited agonists in a dose-dependent fashion with the following ID50 order [apomorphine < PD 128, 907 < 7-(OH) DPAT < quinpirole]. By itself, U 99194A failed to significantly alter the emesis produced by any of the cited agonists, however, it potentiated (3-8 times) the antiemetic effects of sulpride both in reducing the number of shrews vomiting as well as decreasing the mean vomiting frequency with the following ID50 order: PD 128, 907 < 7-(OH) DPAT < quinpirole. However, U 99194A attenuated the potent antiemetic effect of sulpride on the apomorphine-induced emesis. The results suggest that the tested agonists primarily activate dopamine D2 receptors to induce emesis in the least shrew whereas activation of D3 sites potentiate the vomiting action of D2 dopamine receptors.
本研究引入了小麝鼩作为一种新的多巴胺能呕吐动物模型。研究了一种非选择性多巴胺激动剂[阿扑吗啡]、两种D1激动剂[SKF-38393和SKF-82958]、一种偏向D2的激动剂[喹吡罗]以及两种偏向D3的激动剂[7-(OH) DPAT和PD 128,907]的潜在催吐作用。腹腔注射D1激动剂未能诱发呕吐。然而,其他激动剂导致呕吐动物百分比呈剂量依赖性增加,并增强了呕吐的平均频率,其半数有效剂量(ED50)、效价顺序如下:7-(OH) DPAT < 阿扑吗啡 < 喹吡罗 < PD 128,907。在拮抗剂研究中,使用2mg/kg剂量的这些激动剂来诱发呕吐。因此,评估了一种偏向D2的拮抗剂[舒必利]、一种偏向D3的拮抗剂[U 99194A]以及不同剂量的这些拮抗剂组合[舒必利 + U 99194A]对上述激动剂诱发呕吐能力的抑制剂量-反应效应。舒必利以剂量依赖性方式减少了小麝鼩呕吐的数量以及上述激动剂产生的平均呕吐频率,其半数抑制剂量(ID50)顺序如下:[阿扑吗啡 < PD 128,907 < 7-(OH) DPAT < 喹吡罗]。单独使用时,U 99194A未能显著改变任何上述激动剂产生的呕吐,但它增强了(3 - 8倍)舒必利的止吐作用,既减少了呕吐的小麝鼩数量,也降低了平均呕吐频率,其ID50顺序如下:PD 128,907 < 7-(OH) DPAT < 喹吡罗。然而,U 99194A减弱了舒必利对阿扑吗啡诱发呕吐的强效止吐作用。结果表明,所测试的激动剂主要通过激活多巴胺D2受体在小麝鼩中诱发呕吐,而激活D3位点则增强了多巴胺D2受体的呕吐作用。